Why Did DiaMedica Stock Soar 11.48%? Positive Phase 2 Results

On July 18, 2025, Diamedica's stock surged by 11.48% in pre-market trading, driven by positive interim results from its Phase 2 study of DM199 for the treatment of preeclampsia.

DiaMedica Therapeutics Inc. announced that DM199, a recombinant form of the KLK1 protein, demonstrated highly statistically significant and clinically meaningful reductions in both systolic and diastolic blood pressure for combined cohorts 6-9. The study also revealed that DM199 did not cross the placental barrier, indicating a favorable safety profile. Additionally, the drug showed a robust reduction in the uterine artery pulsatility index, suggesting improved placental perfusion and potential disease modification.

Rick Pauls, President and CEO of DiaMedica Therapeutics, highlighted the potential of DM199 as a first-in-class, disease-modifying therapy for preeclampsia, with a promising fetal exposure profile. The company plans to proceed with the enrollment of the dose expansion cohort and initiate enrollment in the fetal growth restriction cohort based on these encouraging results.

Professor Cathy Cluver, the principal investigator of the Phase 2 preeclampsia trial, emphasized the significance of these findings, noting that DM199's ability to safely reduce blood pressure represents a major development in the search for an effective treatment for preeclampsia. The trial is being conducted at Tygerberg Hospital in Cape Town, South Africa, under her direction.